Agents that inhibit the renin-angiotensin system (RAS), such as angiotensin-converting
enzyme (ACE) inhibitors and angiotensin II type 1 (AT1) receptor blockers, have considerable benefit in hypertension and heart failure.
1
,
2
,
3
These compounds decrease hemodynamic stress, increase nitric oxide bioactivity, and
reduce pulse pressure.
4
,
5
,
6
Recent long-term clinical studies have indicated that the addition of an ACE inhibitor
decreases morbidity and mortality in patients with stable coronary artery disease.
7
,
8
Furthermore, we have previously demonstrated that treatment with irbesartan in patients
with early atherosclerosis decreases markers of inflammation that may be sensitive
to the oxidative state in the vasculature.
9
,
10
In the present study, we examine the potential mechanisms by which the addition of
either quinapril or irbesartan can regulate vascular function in patients already
on a regimen of aspirin and atorvastatin therapy.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.Circulation. 1994; 90: 2056-2069
- Enhancing cardiac protection after myocardial infarction.Am Heart J. 2000; 139: S23-28
- Reversing endothelial dysfunction with angiotensin-converting enzyme inhibitors. A new trend?.Circulation. 1996; 94: 240-243
- Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease.J Am Coll Cardiol. 1999; 34: 1995-2001
- Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.Circulation. 2000; 101: 1586-1593
- Maximally reducing cardiovascular risk in the treatment of hypertension.Ann Intern Med. 1988; 109: 36-40
- Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients.N Engl J Med. 2000; 342: 145-153
- Effects of ramipril and vitamin E on atherosclerosis.Circulation. 2001; 103: 919-925
- Irbesartan, an AT1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis.J Am Coll Cardiol. 2001; 37: 440-444
- Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease.J Am Coll Cardiol. 2001; 38: 1662-1667
Article Info
Publication History
Accepted:
January 20,
2003
Received in revised form:
January 20,
2003
Received:
July 8,
2002
Identification
Copyright
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
